Genotype-based versus standard dietary counseling to reduce weight and body fat.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with BMI ≥25 who speak Greek will receive individualized dietary guidance either informed by their genotype or based on conventional dietary guidelines. Participants will attend counseling sessions at the Metropolitan College Dietetics Department and researchers will track changes in body weight and body composition over the intervention period. The trial compares weight loss and fat mass reduction between the genotype-guided arm and the standard counseling arm. Additional measures such as adherence and dietary changes may also be collected to contextualize outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥18 years
* Body mass index (BMI) ≥25 kg/m²
* Greek-speaking (able to read and understand Greek and provide informed consent)
* Willing and able to participate in dietary counseling and study assessments for the duration of the study

Exclusion Criteria:

* Current use of pharmacological treatments for weight loss, including but not limited to GLP-1 receptor agonists, appetite suppressants, or other anti-obesity medications
* Participation in any structured weight-loss intervention or program within the previous 3 months, including commercial weight-loss programs or medically supervised dietary interventions
* Use of medications known to significantly affect body weight or body composition, such as systemic corticosteroids, antipsychotic medications, or medications for thyroid disorders
* Pregnancy or lactation
* Presence of medical conditions that may affect body weight, metabolism, or nutritional status, including untreated thyroid disease, severe gastrointestinal disorders, or endocrine disorders

Where it's running

• Dietetics Department, School of Health Sciences, Metropolitan College
  Marousi, Greece Recruiting

Study contacts

• Principal investigator: Angeliki Kapellou, PhD — Dietetics Department, School of Health Sciences, Metropolitan College
• Study coordinator: Angeliki Kapellou, PhD
• Email: akapellou@mitropolitiko.edu.gr
• Phone: +30 6938406218

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using tirzepatide to improve metabolic health in people with obesity or overweight

  This study is testing if tirzepatide can help people with obesity or being overweight improve their metabolic health and lose weight over 22 weeks.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT05912621

• Optimizing diet and physical activity for taxi drivers

  This study is trying to help taxi drivers who are overweight or obese make healthier choices about their diet and exercise through personalized support and tools.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT05770570

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Concurrent exercise program changes PCSK9 in adults with overweight

  A supervised program of aerobic plus resistance training for eight weeks will test whether it lowers PCSK9 levels in adults who are overweight.

  Recruiting Kastamonu University · Çatalzeytin, Kastamonu · NCT07910916

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.